Orford Keith 4
4 · Calithera Biosciences, Inc. · Filed Jan 27, 2022
Insider Transaction Report
Form 4
Orford Keith
SR. VP, CLINICAL DEVELOPMENT
Transactions
- Award
Employee Stock Option (Right to Buy)
2022-01-25+40,000→ 40,000 totalExercise: $0.44Exp: 2032-01-24→ Common Stock (40,000 underlying)
Footnotes (1)
- [F1]100% of the Option is initially subject to vesting pursuant to the Company's 2014 Equity Incentive Plan. The Option will vest in monthly installments as measured from November 18, 2021 over three years, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction.